Medical Cannabis Use Consent

The qualified patient or the patient’s legal guardian, if the patient is unable to give his/her own consent, must complete this consent form to indicate that the physician explained the information
and, along with the qualified physician, must sign and date the informed consent form.

  1. The federal Government’s classification of marijuana as a SCHEDULE I controlled substance.
    1. The Federal Government has classified marijuana as a Schedule I controlled substance. Schedule I substances are defined, in part, as having:
      1. A high potential for abuse
      2. No currently accepted medical use in treatment in the United States
      3. A lack of accepted safety for use under medical supervision.
      4. Federal law prohibits the manufacture, distribution, and possession of marijuana even in states such as Florida, which have modified their state laws to treat marijuana as a medicine.
      5. When in the possession of or under the influence of medical marijuana, the patient or the patient’s guardian must always have his or her medical marijuana use registry ID card in his or her possession.
  2. The approval and oversight status of marijuana by the FDA.
    1. Marijuana has not been approved by the FDA for marketing as a drug. Therefore, the “manufacture” of marijuana for medical use is not subject to any federal standards, quality control, or other oversight. Marijuana may contain unknown quantities of active ingredients, which may vary in potency, impurities, contaminants, and substances in addition to THC, which is the primary psychoactive chemical component of marijuana.
    2. Some studies suggest that the use of marijuana by individuals may lead to a tolerance to, dependence on, or addiction to marijuana. I understand that if I require increasingly higher doses to achieve the same benefit or if I think that I may be developing a dependence on marijuana, I should contact the office and schedule an appointment to see the physician.
    3. The potential effect that marijuana may have on a patient’s coordination, motor skills, and cognition, including a warning against operating heavy machinery, operating a motor vehicle, or engaging in activities that require a person to be alert or respond quickly.
    4. The use of marijuana can affect coordination, motor skills, and cognition, i.e., the ability to think, judge, and reason. Driving under the influence of cannabis can double the risk of crashing, which escalates if alcohol is also influencing the driver.
    5. While using medical marijuana, I should not drive, operate heavy machinery, or engage in any activities that require me to be alert and/or respond quickly. I should not participate in activities that may be dangerous to myself or others. I understand that if I drive while under the influence of marijuana, I can be arrested for Driving Under the Influence.
  3. Potential effects from the use of marijuana include, but are not limited to, the following:
    1. Dizziness
    2. Anxiety
    3. Confusion
    4. Sedation
    5. Low blood pressure
    6. Impairment of short-term memory
    7. Euphoria
    8. Difficulty in completing complex tasks
    9. Suppression of the body’s immune system
    10. Effect on the production of sex hormones that lead to adverse effects
    11. Inability to concentrate
    12. Impaired motor skills
    13. Paranoia
    14. Psychotic symptoms
    15. General apathy
    16. Depression
    17. Restlessness
    18. Marijuana may exacerbate schizophrenia in a person predisposed to that disorder.
    19. Eating, talking, or drinking in excess
    20. Altered perception of time
    21. Impaired judgment
    22. Many medical authorities claim that the use of medical marijuana, especially by persons younger than 25, can result in long-term problems with attention, memory, learning, drug abuse, and schizophrenia.
  4. I understand that using medical marijuana while consuming alcohol is not recommended. Additional side effects may become present when using both alcohol and marijuana.
  5. I agree to contact Dr. Scot M. DePue and his office if I experience any other side effects listed above, or if I become depressed or psychotic, have suicidal thoughts, or experience crying spells. I will also contact 911 or go to the nearest emergency room if I experience respiratory problems, changes in my normal sleeping patterns, extreme fatigue, increased irritability, or withdraw from my family and/or friends.
  6. The risks, benefits, and drug interactions of marijuana.
    1. Signs or withdrawal can include feelings of depression, sadness, irritability, insomnia, restlessness, agitation, loss of appetite, trouble concentrating, sleep disturbances and unusual tiredness.
    2. Symptoms of marijuana overdose include but are not limited to: nausea, vomiting, hacking cough, heart rhythm disturbances, numbness in the hands, feet, arms, or legs, anxiety attacks, and incapacitation. If I experience any of these symptoms, I agree to either call 911 or go directly to the nearest emergency room.
    3. Numerous drugs are known to interact with marijuana and not all drug interactions are known. Some mixtures of medications can lead to serious and even fatal consequences. I agree to follow the directions of my treating physician for my use of medical marijuana.
    4. Marijuana may increase the risk of bleeding, low blood pressure, elevated blood sugar, liver enzymes, and other bodily systems when taken with herbs and supplements. I agree to call 911 or report to the nearest emergency room if these symptoms appear.
    5. I understand that medical marijuana may have serious risks and may cause low birth weight or other abnormalities in babies. I will advise my physicians if I become pregnant, try to get pregnant, or will be breastfeeding.
  7. The current state of research on the efficiency of marijuana to treat the qualifying conditions set forth in this section.
    1. Cancer
    2. There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for cancers, including glioma. There is evidence to suggest that cannabinoids and the endocannabinoid system more generally may play a role in the cancer regulation processes. Due to a lack of recent high-quality reviews, a research gap exists concerning the effectiveness of cannabis or cannabinoids in treating cancer in general.
    3. There is conclusive evidence that oral cannabinoids are effective antiemetics in the treatment of chemotherapy-induced nausea and vomiting.
    4. There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for cancer-associated anorexia-cachexia syndrome and anorexia nervosa.
  8. Epilepsy
    1. There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for epilepsy.
    2. Recent systematic reviews were unable to identify any randomized controlled trials for evaluating the efficacy of cannabinoids for the treatment of epilepsy. Currently available clinical data therefore consist solely of uncontrolled case series, which do not provide high-quality evidence of efficacy. Randomized trials of the efficacy of cannabidiol for different forms of epilepsy have been completed and await publication.
  9. Glaucoma
    1. There is limited evidence that cannabinoids are an ineffective treatment for improving intraocular pressure associated with glaucoma.
    2. Lower intraocular pressure is a key target for glaucoma treatments. Non-randomized studies in healthy volunteers and glaucoma patients have shown short-term reductions in intraocular pressure with oral, topical eye drops, and intravenous cannabinoids, suggesting the potential for therapeutic benefit. A good-quality systemic review identified a single small trial that found no effect, so the evidence is limited. However, to be effective, treatments targeting lower intraocular pressure must provide continual rather than transient reductions in intraocular pressure. To date, those studies showing positive effects have shown only short-term benefit on intraocular pressure (hours), suggesting a limited potential for cannabinoids in the treatment of glaucoma.
  10. Positive status for human immunodeficiency virus
    1. There is limited evidence that cannabis and oral cannabinoids are effective in increasing appetite and decreasing weight loss associated with HIV/AIDS.
    2. There does not appear to be good-quality primary literature that reported on cannabis or cannabinoids as effective treatments for AIDS wasting syndrome.
    3. There is limited evidence that cannabis and oral cannabinoids are effective, but there does not appear to be good-quality primary literature that reported on cannabis or cannabinoids as effective treatments for AIDS wasting.
  11. Post-traumatic stress disorder
    1. There is limited evidence (a single, small fair-quality trial) that nabilone is effective for improving symptoms of PTSD.
    2. A single, small crossover trial suggests potential benefit from the pharmaceutical cannabinoid nabilone. This limited evidence is most applicable to male veterans and contrasts with non-randomized studies showing limited evidence of a statistical association between cannabis use (plant-derived forms) and increased severity of PTSD symptoms among individuals with PTSD. There are other trials in the process of being conducted and, if successfully completed, they will add substantially to the
      knowledge base.
  12. Amyotrophic lateral sclerosis
      Sizes were small, the duration of the studies was short, and the dose of dronabinol may have been too small to ascertain any activity. The effect of cannabis was not investigated.
  13. Crohn’s disease
    1. There is insufficient evidence to support or refute the conclusion that dronabinol is an effective treatment for the symptoms of irritable bowel syndrome.
    2. Some studies suggest that marijuana in the form of cannabidiol may be beneficial in the treatment of inflammatory bowel disease, including Crohn’s disease.
  14. Anxiety
    1. Evidence shows that medical marijuana is effective in treating generalized anxiety.
  15. Multiple sclerosis
    1. There is substantial evidence that oral cannabinoids are an effective treatment for improving patient-reported MS spasticity symptoms, but limited evidence for an effect on clinically measured spasticity.
    2. Based on evidence from randomized controlled trials included in systematic reviews, an oral cannabis extract, nabiximols, and orally administered THC are probably effective for reducing patient-reported spasticity scores in patients with MS. The effect appears to be modest. These agents have not consistently demonstrated a benefit on clinically measured spasticity indices.
  16. Chronic nonmalignant pain
    1. There is substantial evidence that cannabis is an effective treatment for chronic pain in adults.
    2. The majority of studies on pain evaluated nabiximols outside the United States. Only a handful of studies have evaluated the use of cannabis in the United States, and all of them evaluated cannabis in flower form provided by the National Institute on Drug Abuse. In contrast, many of the cannabis products that are sold in state-regulated markets bear little resemblance to the products that are available for research at the federal level in the US. Pain patients also use topical forms.
    3. That the patient’s de-identified health information contained in the physician certification and medical marijuana use registry may be used for research purposes.

Dr. Scot DePue also informed me of the risks, complications, and expected benefits of any recommended treatment, including the likelihood of success and failure. I acknowledge that Dr. Scot DePue informed me of any alternatives to the recommended treatment, including the alternative of no treatment, and the risks and benefits. There will be NO refunds for not meeting qualifications for the medical card.